<code id='112DC82BA8'></code><style id='112DC82BA8'></style>
    • <acronym id='112DC82BA8'></acronym>
      <center id='112DC82BA8'><center id='112DC82BA8'><tfoot id='112DC82BA8'></tfoot></center><abbr id='112DC82BA8'><dir id='112DC82BA8'><tfoot id='112DC82BA8'></tfoot><noframes id='112DC82BA8'>

    • <optgroup id='112DC82BA8'><strike id='112DC82BA8'><sup id='112DC82BA8'></sup></strike><code id='112DC82BA8'></code></optgroup>
        1. <b id='112DC82BA8'><label id='112DC82BA8'><select id='112DC82BA8'><dt id='112DC82BA8'><span id='112DC82BA8'></span></dt></select></label></b><u id='112DC82BA8'></u>
          <i id='112DC82BA8'><strike id='112DC82BA8'><tt id='112DC82BA8'><pre id='112DC82BA8'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:fashion    Page View:49757
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          A Q&A with the global head of Boehringer Ingelheim's innovation unit
          A Q&A with the global head of Boehringer Ingelheim's innovation unit

          MichelPairetCourtesyBoehringerIngelheimLONDON—Ataneventherelastweek,theGermanpharmaceuticalfirmBoehr

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Bristol 'take

          MollyFerguson/STATSomeday-afterthoughtsonBristolMyersSquibbacquiringMiratiTherapeutics:Atake-underde